|Chemical and physical data|
|Molar mass||146252.08 g·mol−1|
|(what is this?)|
Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies. Tabalumab was developed by Eli Lilly and Company.
A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013. In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab" (PDF). American Medical Association.
- "BAFF Antibody: Tabalumab, LY2127399". Lilly USA, LLC. Archived from the original on 12 August 2013.
- "Press Release Archive - Press Release Archives".
- "Lilly Halts Tabalumab Development for Lupus". 2 October 2014.
Now dropped by Lilly due to lack of efficacy.